Related Experiment Videos
Basic biology and clinical application of specific cyclooxygenase-2 inhibitors
L J Crofford1, P E Lipsky, P Brooks
1University of Michigan, Ann Arbor 48109-0680, USA.
Abstract:
In summary, COX-2 is a highly regulated gene product that catalyzes the local production of PGs in pathologic and physiologic situations (Figure 1). It is clear that COX-2 is the isoform responsible for production of the PGs that mediate inflammation, pain, and fever. However, the role for COX-2 in normal physiology is still being defined. Specific COX-2 inhibitors represent a significant conceptual advance in therapy for patients with arthritis. Although there is no expectation of superior efficacy, clinical trials suggest that efficacy will be comparable with that of nonselective NSAIDs. Clinical trials demonstrate the potential for clinically meaningful reductions in the incidence of the most serious GI complications found with nonselective NSAIDs, i.e., ulcer, perforation, and GI bleeding. Over the next several years, treatment of large numbers of patients with specific COX-2 inhibitors will help to define the biology of COX-2. The magnitude of this advance in the therapy of rheumatic diseases is yet to be accurately determined, but the development of specific COX-2 inhibitors may afford significant new treatment options for many patients.
Insights
Cyclooxygenase-2 (COX-2) produces prostaglandins mediating inflammation, pain, and fever. Specific COX-2 inhibitors offer comparable efficacy to NSAIDs with reduced gastrointestinal complications for arthritis patients.
Area of Science:
- Biochemistry
- Pharmacology
- Rheumatology
Background:
- Cyclooxygenase-2 (COX-2) is a key enzyme in prostaglandin synthesis.
- COX-2 mediates inflammation, pain, and fever, but its role in normal physiology is under investigation.
- Nonselective NSAIDs carry risks of serious gastrointestinal complications.
Purpose of the Study:
- To review the role of COX-2 in health and disease.
- To evaluate the therapeutic potential of specific COX-2 inhibitors in arthritis.
- To assess the safety profile of COX-2 inhibitors, particularly regarding gastrointestinal (GI) effects.
Main Methods:
- Review of existing clinical trial data on specific COX-2 inhibitors.
- Comparison of efficacy and safety profiles with nonselective NSAIDs.
- Analysis of the biological mechanisms underlying COX-2 activity.
Main Results:
- Specific COX-2 inhibitors show comparable efficacy to nonselective NSAIDs in treating arthritis.
- Clinical trials indicate a significant reduction in serious GI complications (ulcer, perforation, bleeding) with COX-2 inhibitors.
- The precise role of COX-2 in normal physiological processes requires further elucidation.
Conclusions:
- Specific COX-2 inhibitors represent a significant advancement in arthritis therapy.
- These agents offer a potentially safer alternative to nonselective NSAIDs due to a lower risk of GI adverse events.
- Further research and long-term patient treatment will clarify the full biological and therapeutic impact of COX-2 inhibition.